## EW: Edwards Lifesciences Corporatio - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.2% below STRENGTH zone (3.0-6.0%); PEG 4.78 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($80.91)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Quadrant Capital Group LLC Grows Stock Position in Edwards Lifesciences Corporation $EW**
- Source: MarketBeat | 20251201T112247 | Somewhat-Bullish | Relevance: 100%
- Quadrant Capital Group LLC significantly increased its stake in Edwards Lifesciences (EW) by 40.2%, now holding 14,955 shares valued at $1.17 million. This move coincides with other institutional investors boosting their positions, leading to institutional ownership of 79.46% of the stock. Edwards Lifesciences also reported strong earnings, beating revenue and EPS expectations, and analysts maintain a "Moderate Buy" rating for the company.

**2. HALPER SADEH LLC ENCOURAGES EDWARDS LIFESCIENCES CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS**
- Source: Barchart.com | 20251130T203127 | Neutral | Relevance: 99%
- Halper Sadeh LLC, an investor rights law firm, is encouraging shareholders of Edwards Lifesciences Corporation (NYSE: EW) to contact them regarding potential breaches of fiduciary duties by the company's officers and directors. The firm offers to represent shareholders on a contingent fee basis to pursue corporate governance reforms, recovery of funds, and other relief. This initiative aims to enhance shareholder value through improved company policies and oversight.

**3. Laurel Wealth Advisors LLC Raises Position in Edwards Lifesciences Corporation $EW**
- Source: MarketBeat | 20251130T112125 | Somewhat-Bullish | Relevance: 98%
- Laurel Wealth Advisors LLC significantly increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 7,721.7% during Q2, now holding 5,397 shares valued at $422,000. Edwards Lifesciences reported strong Q3 earnings, beating analyst estimates, and provided positive FY2025 guidance. Despite some insider selling, institutional ownership remains high, and analysts maintain a "Moderate Buy" rating with an average price target of $91.39.

**4. First National Advisers LLC Buys 9,644 Shares of Edwards Lifesciences Corporation $EW**
- Source: MarketBeat | 20251130T101153 | Somewhat-Bullish | Relevance: 98%
- First National Advisers LLC has increased its stake in Edwards Lifesciences Corporation (EW) by 30.3%, acquiring an additional 9,644 shares to bring their total holdings to 41,484 shares valued at approximately $3.245 million. This comes after Edwards Lifesciences reported strong Q3 earnings, beating estimates and raising its FY2025 EPS guidance. The company maintains a "Moderate Buy" consensus rating from analysts, with a target price of $91.39, despite some insider selling.

**5. HALPER SADEH LLC ENCOURAGES EDWARDS LIFESCIENCES CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS**
- Source: Finviz | 20251130T152900 | Neutral | Relevance: 98%
- Halper Sadeh LLC, an investor rights law firm, is investigating potential breaches of fiduciary duties by officers and directors of Edwards Lifesciences Corporation (NYSE: EW). The firm encourages current long-term shareholders to contact them to discuss their legal rights, which may include seeking corporate governance reforms or financial incentives. Their participation could help improve company policies and enhance shareholder value.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Barclays | $103 | $99 | +4% |
| 2025-12-05 | Canaccord Genui | $89 | $84 | +6% |
| 2025-12-05 | Stifel | $100 | $95 | +5% |
| 2025-12-05 | UBS | $92 | $90 | +2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Barclays | main | Overweight |
| 2025-12-05 | Canaccord Genui | main | Hold |
| 2025-12-05 | Stifel | main | Buy |
| 2025-12-05 | UBS | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.06M) |
| Sells | 3 ($0.90M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.5%)
- Blackrock Inc.: 9.4% (-2.4%)
- JPMORGAN CHASE & CO: 8.6% (+87.2%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.6% (+4.9%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.6% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 4.8x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 9 raises (avg +4%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 4.78 signals overvaluation risk, limited margin of safety. Forward P/E 29.5x stretched relative to 11% growth. Quality metrics strong (margin 23%). Balance sheet: strong liquidity (4.0x), low leverage (D/E 0.30). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $49.3B |
| Beta | 0.97 |
| 52W Range | $65.94 - $87.89 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.78 |
| Forward P/E | 29.5 |
| Current P/E | 32.8 |
| YoY Growth | 11.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 0.3% to -3.2% (-3.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.2pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.11x) but short-term weakness (below SMA20). RSI neutral at 54.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.24% (CS: 18) | Weak |
| RSI_14 | 54.5 | Neutral |
| MACD Histogram | -0.28 | Bearish |
| vs SMA20 | 0.997x | Below |
| vs SMA50 | 1.058x | Above |
| vs SMA200 | 1.106x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $84.71
- **Stop Loss:** $80.91 (4.5% risk)
- **Target:** $88.51 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 263
- **Position Value:** $22,278.73
- **Portfolio %:** 22.28%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-11 (Est: $0.62)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.59 | $0.67 | +12.6% |
| 2025Q2 | $0.62 | $0.67 | +7.6% |
| 2025Q1 | $0.60 | $0.64 | +7.5% |
| 2024Q4 | $0.55 | $0.59 | +6.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*